Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - FDA CLEARANCE OF IND APPLICATION FOR CSA OPHTHALMIC GEL | 3 | HKEx | ||
ZHAOKE OPHTHALMOLOGY Aktie jetzt für 0€ handeln | |||||
19.05. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF NEW DRUG APPLICATION FOR CSA OPHTHALMIC GEL | - | HKEx | ||
16.05. | ZHAOKE OPHTH-B (06622): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 16, 2025 | - | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 16, 2025 | - | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED RE-ELECTION OF THE RETIRING ... | 1 | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024 | - | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): 2024 ANNUAL REPORT | - | HKEx | ||
17.04. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN THE ADDITIONAL PHASE III CLINICAL TRIAL OF CYCLOSPORINE A (CSA) OPHTHALMIC ... | - | HKEx | ||
16.04. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERING INTO THREE DISTRIBUTION AGREEMENTS WITH INTERPHARMA TO COMMERCIALIZE NVK002, BRIMOCHO TM PF ... | 1 | HKEx | ||
11.04. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - UPDATES ON BRIMOCHOL TM PF FOR PRESBYOPIA | 1 | HKEx | ||
01.04. | ZHAOKE OPHTH-B (06622): CONNECTED TRANSACTION ANNOUNCEMENT RENEWAL OF THE LEASE AGREEMENT | 1 | HKEx | ||
24.03. | ZHAOKE OPHTH-B (06622): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION OF WEALTH ... | - | HKEx | ||
07.03. | ZHAOKE OPHTH-B (06622): NOTICE OF BOARD MEETING | - | HKEx | ||
18.02. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 18.02.2025 | 600 | Xetra Newsboard | The following instruments on XETRA do have their first trading 18.02.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.02.2025
Aktien
1 GB00BN0VZ646 Ferrari Group PLC
2... ► Artikel lesen | |
13.01. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERING INTO DISTRIBUTION AGREEMENT WITH AFT PHARMACEUTICALS TO COMMERCIALIZE BRIMOCHOL TM PF IN AUSTRALIA ... | 2 | HKEx | ||
02.01. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF ABBREVIATED NEW DRUG APPLICATION FOR NVK002 FOR TREATMENT OF MYOPIA PROGRESSION IN ... | 3 | HKEx | ||
02.01. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - POSITIVE TOP-LINE RESULTS FROM TAB014 PHASE III CLINICAL TRIAL FOR THE TREATMENT OF WAMD | 1 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |